Research Article

RP-HPLC Method for Simultaneous Estimation of Cefepime Hydrochloride and Tazobactam Sodium in Bulk and Pharmaceuticals

Sagar R. Tamboli and Dipak D. Patil

Department of Quality Assurance, H. R. Patel Institute of Pharmaceutical Education and Research, Karvand Naka, Shirpur 425405, India

Correspondence should be addressed to Dipak D. Patil; dipakpatil888@rediffmail.com

Received 31 May 2013; Revised 10 August 2013; Accepted 24 August 2013

A precise, accurate, sensitive and robust RP-HPLC method was developed for cefepime hydrochloride and tazobactam sodium in bulk and pharmaceutical formulation. Chromatographic separation was achieved on Princeton SPHER-100 C-18 column (250 mm × 4.6 mm i.d., 5 μm) at ambient temperature. A binary mobile phase consisting of 25 mM potassium dihydrogen phosphate buffer, pH 6.2 and acetonitrile (94:6, v/v) was delivered through a column at a flow rate of 1 mL/min. Measurement was performed at a wavelength 210 nm. The method was linear over the concentration range of 4–24 μg/mL (r² = 0.9977) for cefepime and 0.5–3.0 μg/mL (r² = 0.9974) for tazobactam. The percentage content found for cefepime was 101.12 ± 0.49 and for tazobactam was 101.33 ± 1.17 in the pharmaceutical formulation. The method was validated for linearity, precision, accuracy, sensitivity and robustness as per ICH Q2 (R1) guideline.

1. Introduction

Cefepime hydrochloride (CEFE) is fourth-generation, semisynthetic, broad spectrum, cephalosporin antibiotic for parenteral administration. Chemically, it is 1-[(6R, 7R)-7-[(2-Amino-4-thiazolyl)-glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methylpyrrolidinium chloride, 72-(Z)-(O-methyloxime), monohydrate (Figure 1). CEFE is a zwitterionic oxymono β-lactam with an amino-thiazole side chain, which enhances the ability of CEFE to penetrate rapidly the outer cell membrane of gram-negative bacteria. CEFE used in the treatment of moderate-to-severe infections such as pneumonia, uncomplicated urinary tract infections, skin and soft tissue infections, intra-abdominal infections and febrile neutropenia.

Tazobactam sodium (TAZO) is chemically known as (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1, 2, 3-triazol-1-ylmethyl)-4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid 4,4-dioxide (Figure 1). TAZO is semisynthetic parenteral penicillin. TAZO is a β-lactamase inhibitor with a broad spectrum of antibacterial activity against most gram positive, gram negative aerobic bacteria and anaerobic bacteria.

Megapime XP is a sterile combination of CEFE and TAZO available as a dry powder for injection. The fixed dose combination of CEFE and TAZO is used parenterally for the treatment of moderate to severe infection caused by or suspected of being caused by susceptible β-lactamases producing bacteria, while CEFE alone would be ineffective. CEFE and TAZO combination used for the treatment of uncomplicated and complicated urinary tract infection, uncomplicated skin and skin structure infection and complicated intra-abdominal infection.

A literature survey revealed that several liquid chromatography methods had been reported for the determination of CEFE alone [1–4] as well as for stability and degradation study [5–9].

CEFE in combination with other drugs had been estimated by numerous liquid chromatography methods [1, 10–19]. TAZO was also successfully determined by HPLC [20–26].
2. Experimental

2.1. Instrumentation. Chromatographic separation was performed using chromatography system equipped with the Agilent G1315D diode array detector. Ez-Chrome Elite software was employed for data collecting and processing.

2.2. Reagents and Materials. CEFE and TAZO reference standard (RS) was obtained from Alembic LTD, Vadodara, India. Megapime XP, a fixed dose combination of CEFE and TAZO was purchased from the local pharmacy. Acetonitrile (HPLC grade) and potassium dihydrogen phosphate of AR grade were obtained from Merck, Mumbai.

2.3. Chromatography Condition. Chromatographic separation was performed on Princeton SPHER-100 C-18 stainless steel column with dimensions of 250 × 4.6 mm i.d., 5 μm particle size. A binary mobile phase consisting of 25 mM potassium dihydrogen phosphate buffer, pH 6.2 and acetonitrile (94:6, v/v) was delivered through a column at a flow rate of 1 mL/min. The phosphate buffer, pH 6.2 and acetonitrile were filtered separately through a 0.45 μm membrane filter paper, mixed. The mobile phase was degassed before use. HPLC analysis was performed at ambient temperature with detection at 210 nm. The injection volume was 20 μL.

2.4. Preparation of Standard Stock Solution

2.4.1. Standard Stock Solution of CEFE (100 μg/mL). An accurately weighed quantity of powder equivalent to 10.0 mg of CEFE was transferred to 100 mL volumetric flask. The drug was dissolved and diluted to the mark with distilled water.

2.4.2. Standard Stock Solution of TAZO (10 μg/mL). An accurately weighed quantity of powder equivalent to 10.0 mg of TAZO was transferred to 100 mL volumetric flask. The drug was dissolved and diluted to the mark with distilled water. An aliquot of about 10.0 mL was transferred to 100 mL volumetric flask and diluted with distilled water.

2.5. Analysis of Laboratory Mixture

2.5.1. Standard Solution (100 μg/mL of CEFE and 12.5 μg/mL of TAZO). An accurately weighed quantity of 80.0 mg CEFE and 10.0 mg TAZO was transferred to 100.0 mL volumetric flask. The volume was adjusted up to the mark to obtain 800.0 μg/mL of CEFE and 100.0 μg/mL of TAZO. Then aliquot of about 12.5 mL of above CEFE and TAZO solution was diluted up to 100.0 mL.

2.5.2. Working Standard Solution (12 μg/mL of CEFE and 1.5 μg/mL of TAZO). An aliquot of about 1.2 mL stock solution of 100 and 12.5 μg/mL of solution of CEFE and TAZO was transferred to 10.0 mL volumetric flask. The volume was adjusted up to the mark to obtain 12 μg/mL of CEFE and 1.5 μg/mL of TAZO. Each working standard solution was analyzed six times as per the optimized chromatographic condition. The chromatogram of CEFE and TAZO has been shown in Figure 2.

2.6. Assay of Marketed Formulation

2.6.1. Sample Solution (100 μg/mL of CEFE and 12.5 μg/mL of TAZO). A quantity of megapime XP powder of about 19.8 mg (equivalent to 10 mg of CEFE and 1.25 mg of TAZO) was transferred to 100.0 mL volumetric flask. The powder was dissolved in water and sonicated for 10 min. The volume was made up to the mark with water.

2.6.2. Working Sample Solution (12 μg/mL of CEFE and 1.5 μg/mL of TAZO). An aliquot of about 1.2 mL of sample
solution of 100 μg/mL CEFE and 12.5 μg/mL TAZO was transferred to 10.0 mL volumetric flask. The volume was adjusted up to the mark to obtain 12 μg/mL of CEFE and 1.5 μg/mL of TAZO. The sample was analyzed six times as per the optimized chromatographic condition.

2.7. Validation. The method was validated for system suitability, linearity, range, precision, accuracy, limit of detection (LOD), limit of quantitation (LOQ), specificity and robustness as per ICH Q2 (R1) guidelines [27]. System suitability parameters of developed HPLC method were determined by analyzing standard working solution. Chromatographic parameters such as retention time, asymmetry, theoretical plates, capacity factor and resolution were determined. Linearity was calculated with six concentration levels of CEFE and TAZO. Precision was measured both intraday and interday. In the intraday study, concentration of CEFE and TAZO was analyzed three times on the same day at an interval of an hour. In an interday study, the concentration of CEFE and TAZO was analyzed on three different days. Accuracy was studied by the measurement of recovery at three different levels such as 80%, 100% and 120% of the amount expected in the formulation. LOD and LOQ of the method was studied combined dosage form.

2.8. Linearity study. Linear relationship between signal (peak area) and concentration was calculated by linear regression using standard working solution. The graph was found linear in the range of 4–24 μg/mL for CEFE and 0.5–3.0 μg/mL for TAZO (Table 2).

The assay results obtained has shown that the method is suitable for the routine analysis of CEFE and TAZO in their combined dosage form.

3.2. Validation

3.2.1. System Suitability. System suitability parameters of the developed HPLC method were determined (Table 2). The parameters like capacity factor, theoretical plates and asymmetry factor were within range of the specified limit.

3.2.2. Linearity Study. Linearity graph of working standard solution concentration versus peak area was plotted for CEFE and TAZO. The graph was found linear in the range of 4–24 μg/mL for CEFE and 0.5–3 μg/mL for TAZO (Table 2).

3.2.3. Precision. Precision of the method was verified by repeatability and intermediate precision study. Repeatability was measured by determining % RSD of multiple injections of a homogenous sample of 12 μg/mL of CEFE and 1.5 μg/mL of TAZO which was found to be 0.92 and 1.09, respectively. Intra-day precision was calculated by determining % RSD of analysis of 4, 8 and 12 μg/mL of CEFE and 0.5, 1.0 and 1.5 μg/mL of TAZO on the same day which was found to be 0.51 and 0.29 respectively. Inter day precision was checked by repeating an analysis of the same concentrations of CEFE and TAZO on three different days having % RSD of 0.27 and

3. Results

In the present work, a RP-HPLC method was developed and validated for the simultaneous estimation of CEFE and TAZO in bulk and pharmaceutical dosage form. The final optimized chromatographic conditions were PrincetonSPHER-100 C-18 column (250 mm × 4.6 mm i.d., 5 μm) as stationary phase eluted with a binary mobile phase consisting of 25 mM potassium dihydrogen phosphate buffer, pH 6.2 and acetonitrile (94:6, v/v). The flow rate of mobile phase was 1 mL/min with detection wavelength 210 nm. By using optimized chromatographic conditions, CEFE and TAZO were eluted at 9.97 min and 7.61 min, respectively (Figure 2).

3.1. Assay of Marketed Formulation. The assay result of CEFE and TAZO in pharmaceutical dosage form was comparable with the value claimed on the vial. The percentage content found for CEFE was 101.12 ± 0.49 and for TAZO was 101.33 ± 1.17 (Table 1).

![Table 1: Analysis of marketed formulation.](image1)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>CEFE (μg/mL)</th>
<th>TAZO (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amount taken (μg/mL)</td>
<td>12.0</td>
<td>1.5</td>
</tr>
<tr>
<td>Amount found (μg/mL)</td>
<td>12.09</td>
<td>1.5199</td>
</tr>
<tr>
<td>% Assay ± SD (n = 6)</td>
<td>101.12 ± 0.49</td>
<td>101.33 ± 1.17</td>
</tr>
<tr>
<td>% RSD</td>
<td>0.48</td>
<td>1.15</td>
</tr>
</tbody>
</table>

![Table 2: Results of validation parameters.](image2)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>CEFE (μg/mL)</th>
<th>TAZO (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>System suitability parameters (n = 5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retention time (min) ± % RSD</td>
<td>10.49 ± 0.68</td>
<td>7.69 ± 0.83</td>
</tr>
<tr>
<td>Capacity factor ± % RSD</td>
<td>3.19 ± 0.35</td>
<td>2.07 ± 0.84</td>
</tr>
<tr>
<td>Theoretical plate ± % RSD</td>
<td>10505 ± 1.11</td>
<td>12957 ± 0.65</td>
</tr>
<tr>
<td>Asymmetry factor ± % RSD</td>
<td>1.02 ± 0.92</td>
<td>0.99 ± 1.24</td>
</tr>
<tr>
<td>Linearity study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Linear range (μg/mL)</td>
<td>4–24</td>
<td>0.5–3.0</td>
</tr>
<tr>
<td>Slope</td>
<td>73730</td>
<td>48802</td>
</tr>
<tr>
<td>Intercept</td>
<td>27477</td>
<td>23279</td>
</tr>
<tr>
<td>Correlation coefficient (r²)</td>
<td>0.9977</td>
<td>0.9974</td>
</tr>
<tr>
<td>Precision (n = 3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Repeatability (% RSD)</td>
<td>0.92</td>
<td>1.09</td>
</tr>
<tr>
<td>Interday (% RSD)</td>
<td>0.27</td>
<td>0.54</td>
</tr>
<tr>
<td>Intraday (% RSD)</td>
<td>0.51</td>
<td>0.29</td>
</tr>
<tr>
<td>Accuracy (n = 3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80% ± (% RSD)</td>
<td>102.22 ± 0.25</td>
<td>99.92 ± 1.09</td>
</tr>
<tr>
<td>100% ± (% RSD)</td>
<td>103.01 ± 0.93</td>
<td>102.02 ± 0.76</td>
</tr>
<tr>
<td>120% ± (% RSD)</td>
<td>100.95 ± 0.68</td>
<td>99.82 ± 1.34</td>
</tr>
<tr>
<td>Specificity study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percent drug remained</td>
<td>95.94</td>
<td>82.29</td>
</tr>
<tr>
<td>Acid stress</td>
<td>94.95</td>
<td>98.63</td>
</tr>
<tr>
<td>Base stress</td>
<td>67.19</td>
<td>87.4</td>
</tr>
<tr>
<td>Oxidation stress</td>
<td>92.28</td>
<td>91.27</td>
</tr>
</tbody>
</table>
3.2.4. Accuracy. To study the reliability, suitability and accuracy of the method recovery study was carried out by standard addition method at 80, 100 and 120% of label claim. At each level, three determinations were carried out. The % RSD value of % recovery was less 2 indicate that the developed method was accurate one (Table 2).

3.2.5. Sensitivity. The quantitation limit is a parameter of the quantitative assay at low levels of analyte in sample matrices and is used particularly for the determination of impurities and degradation products. LOD and LOQ were found to be 0.26 µg/mL and 0.80 µg/mL for CEFE and 0.020 µg/mL and 0.062 µg/mL for TAZO, respectively.

3.2.6. Specificity. Forced degradation study was performed to evaluate the specificity of the proposed method. Sample for degradation study was prepared by refluxing the CEFE solution at 70°C with 1 M HCl, 0.5 M NaOH and exposed to 5% w/v H₂O₂ for 10 min. For TAZO, solution was refluxed at 70°C with 0.01 M HCl, 0.01 M NaOH and exposed to 0.1% w/v H₂O₂ for 10 min. In addition, the CEFE and TAZO solutions were subjected to thermal degradations as for CEFE at 105°C for 88 h and for TAZO at 105°C for 24 h. After specified time, samples were removed, allowed to cool and diluted to the same concentration as the standard solution. The samples were analyzed by the optimized chromatographic conditions against a control sample. The result of degradation study has shown in Figures 3, 4 and Table 2.

No interference was found at the Rt of CEFE and TAZO. The peak purity value for CEFE and TAZO was found to be more than the threshold value confirms no interference of degradation products, impurity or any formulation excipient. Thus, the developed method was found to be a specific one.

3.2.7. Robustness. The HPLC method robustness was carried out by deliberate small variation in the flow rate, mobile phase composition and wavelength. The robustness study of HPLC method was carried out statistically by using Design Expert software. Robustness testing was performed in order to obtain information about critical parameters affecting the selected response (peak area, retention time and found concentration). Multivariate approach was utilized to study the effect of simultaneous variations of experimental variables on the selected responses.

A three factor face centered design (FCD) was employed to evaluate the effects of three independent factors, namely, the percentage of mobile phase (X₁); flow rate (X₂); and wavelength (X₃) on peak area (R₁), retention time (R₂) and found concentration (R₃). The investigated range of experimental variables has shown in Table 3.

The coefficients of the second order polynomial model were estimated by the least squares regression. The model equation for CEFE and TAZO for selected response R was as follows:

\[
R = 9.162E + 005 + 10738.40X₁ - 28458.00X₂
- 53886.20X₃ + 8109.25X₁X₂ - 15290.50X₁X₃
- 9273.50X₂X₃ + 9523.15X₁² - 11445.85X₂²
- 21314.85X₃²
\]

From the experimental response, it was found that an increase in wavelength causes decrease in mean peak area (and found concentration), while the organic modifier had no such effect in case of CEFE and TAZO. As flow rate decreases, the retention time of CEFE and TAZO becomes longer. So, a precautionary statement about wavelength is to be included in procedure.

4. Discussion

The RP-HPLC method has been developed for the simultaneous determination of CEFE and TAZO in bulk and pharmaceutical dosage form. TAZO has UV absorption below 210 nm. As below 210 nm, the molecular oxygen and absorption of solvent will interfere in quantitative analysis. The TAZO estimation by UV spectroscopy was found to be difficult. Therefore, RP-HPLC method was developed for simultaneous estimation of CEFE and TAZO in bulk and pharmaceutical dosage form. Advantages of proposed HPLC method were as simple, easy mobile phase preparation, run time < 12 min and economical one.

A buffer concentration of 25 mM phosphate buffer was used in mobile phase as it is a good compromise. At higher buffer concentrations (>50 mM) provide increased buffer capacity but may not be soluble in the mobile phase [29]. Higher buffer concentration also may adversely affect the operation of HPLC system constructed of stainless steel [29]. The phosphate, one of inorganic buffer is marginally soluble in a solution containing a high concentration of organic. The phosphate buffer used for controlling pH in the range 2.1 to 3.1 or 6.2 to 8.2 allows detection at 210 nm or lower [29].

Acetonitrile was the preferred component in mobile phase as it allows the quantitative measurements below 210 nm.

It is evident from a system suitability test that the method developed for CEFE and TAZO combination had passed the standards of regulatory requirements.
The method was found to be linear over the wide range and to be useful for bulk and pharmaceutical analyses. The method was successfully applied to bulk material and pharmaceutical formulation assay. From specificity study, it was observed that drug combination is free from excipient interaction and method is suitable for analysis of CEFE and TAZO in the presence of their degradation products or impurity. According to ICH Q2 (R1) guideline, the robustness of an analytical procedure refers to its capability to remain unaffected by small and deliberate variation in method parameters. All the 18 experimental runs suggested by the design expert software were performed in randomized order to minimize the effects of uncontrolled factors that may introduce a bias in response. Experimental results were computed using Design-Expert version 8.0.6 software [28]. From the results of robustness study it was observed that the proposed method was found to be robust when deliberate variations were made in the optimized chromatographic conditions.

5. Conclusion

The proposed RP-HPLC method is simple, rapid, precise, accurate and robust for the simultaneous estimation of CEFE and TAZO in bulk and its injection formulation. Hence, it can be conveniently adopted for the routine quality control analysis.

Conflict of Interests

The authors of the paper do not have a direct financial relation with the commercial identity mentioned in the paper. The
authors report no declaration of interests and do not have any conflict of interests.

References
